U.S. markets closed

CLDX Jan 2024 25.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
7.550.00 (0.00%)
As of 09:42AM EDT. Market open.
Full screen
Previous Close7.55
Expire Date2024-01-19
Day's Range7.55 - 7.55
Contract RangeN/A
Open Interest21
  • GlobeNewswire

    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

    HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

  • TipRanks

    Billionaire Andreas Halvorsen Bets Big on These 2 High-Upside Stocks

    Even after some recent positive trading sessions, the stock markets are still registering heavy losses this year. The S&P is down 18%, and the NASDAQ remains in bear territory with a 26% year-to-date loss. But these broad-based market losses have also opened up opportunities, as many stocks have fallen for no fault of their own. Some of the Street’s most legendary investors are not shying away from buying in, even in this bearish environment. Andreas Halvorsen, a former Tiger Cub and the billion

  • Zacks

    Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?

    The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.